B-cell lymphoma(Jenthera)(B-cell lymphoma(Jenthera)) - 在研适应症：非霍奇金淋巴瘤_专利_临床

概要

基本信息

药物类型

CAR-T

别名-

靶点-

作用机制-

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

非霍奇金淋巴瘤

非在研适应症-

原研机构

Jenthera Therapeutics, Inc.初创企业

在研机构

Jenthera Therapeutics, Inc.初创企业

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

100 项与 B-cell lymphoma(Jenthera) 相关的临床结果

登录后查看更多信息

100 项与 B-cell lymphoma(Jenthera) 相关的转化医学

登录后查看更多信息

100 项与 B-cell lymphoma(Jenthera) 相关的专利（医药）

登录后查看更多信息

1

项与 B-cell lymphoma(Jenthera) 相关的文献（医药）

Oncology Letters

Newer combination treatments for breast cancer coexisting with acute myeloid leukemia in the novel regimens era: A case report and literature review

Article

作者: Tian, Tian ; Guo, Xiaonan ; Zhang, Jingnan ; Qiao, Shukai ; Li, Yang ; Xing, Lina

The occurrence of acute myeloid leukemia (AML) with a simultaneous diagnosis of breast cancer (BC) is rarely reported in the literature. The present study reports the case of a 50-year-old female patient diagnosed with AML coexisting with metastatic BC. Following one cycle of treatment with azacytidine in combination with oral venetoclax for AML, the patient achieved complete remission with incomplete hematological recovery. In addition, the mass in the left breast was smaller following adjuvant chemotherapy. However, due to a refusal from the patient to accept an allogeneic hematopoietic stem cell transplantation (allo-HSCT), the patient succumbed 3 months after diagnosis due to septic shock from neutropenia following the third cycle of chemotherapy. Altogether, the present case report highlighted the application of venetoclax, an oral selective B-cell lymphoma-2 inhibitor, both in hematologic malignancies and solid neoplasms, as an effective therapeutic regimen. Considering the fatality rate associated with AML, allo-HSCT is the only available strategy that can be used to achieve the long-term survival of patients with AML and BC.

100 项与 B-cell lymphoma(Jenthera) 相关的药物交易

登录后查看更多信息